M Ventures, a venture capital firm, led a $37.5m Series A round in Nucleome Therapeutics, a biotechnology company,. with participation from Johnson and Johnson Innovation-JJDC. Pfizer Ventures, British Patient Capital and Oxford Science Enterprises. “We have already made significant progress by mapping genes to genetics in a number of human immune cell types and discovering the first wave of potential first-in-class autoimmune disease targets. The completion of this oversubscribed round with such a high-calibre group of global life science investors is a recognition of the significance of Nucleome’s platform and its potential to support the development of an exciting portfolio of first-in-class targets for autoimmune diseases,” Danuta Jeziorska, Nucleome Therapeutics Chief Executive Officer and Co-founder.